


exact bonds :
5-6

G1:O,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 18:CLASS 19:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s 11
SAMPLE SEARCH INITIATED 09:59:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 537 TO ITERATE

100.0% PROCESSED 537 ITERATIONS 14 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 9350 TO 12130
PROJECTED ANSWERS: 56 TO 504

L2 14 SEA SSS SAM L1

=> s 11 full
FULL SEARCH INITIATED 09:59:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 11331 TO ITERATE

100.0% PROCESSED 11331 ITERATIONS 270 ANSWERS
SEARCH TIME: 00.00.01

L3 270 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
161.33 161.54

FILE 'CAPLUS' ENTERED AT 09:59:24 ON 27 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Dec 2005 VOL 144 ISS 1
FILE LAST UPDATED: 26 Dec 2005 (20051226/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> s 13
L4 7 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2005216669 CAPLUS
 DOCUMENT NUMBER: 142:297985
 TITLE: Preparation of thienopyrrole carboxamides as glycogen phosphorylase inhibitors
 INVENTOR(S): Bennett, Stuart Norman Lile; Simpson, Iain
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl. '72 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020986	A1	20050310	WO 2004-GB3622	20040825
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:		GB 2003-20241	A 20030829	
		GB 2003-24788	A 20031024	

OTHER SOURCE(S): MARPAT 142:297985
 GI



AB Title compds. represented by the formula I [wherein A = phenylene or heteroarylene; n = 0-2; R1 = independently halo, NO2, CN, carbamoyl, etc.; R2R3 = heterocyclic ring; R4R5 = -SC(R6):C(R7)- or -C(R7):C(R6)S-; R6, R7


L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 = independently H, halo, OH, carboxy, etc.; and pharmaceutically acceptable salts or prodrugs thereof] were prepd. as glycogen phosphorylase inhibitors (no data). For example, II was given in a multi-step synthesis starting from the reaction of Me 2-chlorothiophene-3-carboxaldehyde with Me azidoacetate. I and their pharmaceutical compns. are useful as glycogen phosphorylase inhibitors for the treatment of disease states assocd. with increased glycogen phosphorylase activity (no data).

IT 403859-99-4P 596847-02-8P 846546-09-6P
 846546-20-1P 847658-08-6P 847658-09-7P
 847658-10-0P 847658-13-3P 847658-14-4P
 847658-22-4P 847658-23-5P 847658-24-6P
 847658-25-7P 847658-26-8P 847658-27-9P
 847658-28-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of thienopyrrole carboxamides as glycogen phosphorylase inhibitors)


RN 403859-99-4 CAPLUS
 CN Carbamic acid, [(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 596847-02-8 CAPLUS
 CN Carbamic acid, [(1R,2R)-2-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 846546-09-6 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl]-2-chloro-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


Absolute stereochemistry.



● HCl

RN 846546-20-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847658-08-6 CAPLUS
 CN Carbamic acid, [(1R,2R)-2-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, (2-hydroxyethyl)-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 847658-09-7 CAPLUS
 CN Carbamic acid, [(1R,2R)-2-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-[2-(tetrahydro-2H-pyran-2-yl)oxylethyl]-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847658-10-0 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl]-2-chloro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 596846-31-0
 CMF C16 H14 Cl N3 O S

Absolute stereochemistry.




CM 2




RN 847658-13-3 CAPLUS
 CN Carbanic acid, [(1R,2R)-2-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl][(2S)-2,3-dihydroxypropyl]-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847658-14-4 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847658-22-4 CAPLUS


L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 847658-25-7 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1-[(2,4-dihydroxy-1-oxobutyl)amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847658-26-8 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1-[(2R)-2,4-dihydroxy-1-oxobutyl]amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847658-27-9 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1-[(2S)-2,4-dihydroxy-1-oxobutyl]amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.




RN 847658-23-5 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[(2R)-4-bromo-2-hydroxy-1-oxobutyl)amino]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847658-24-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[(2S)-4-bromo-2-hydroxy-1-oxobutyl)amino]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Absolute stereochemistry.




● HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2005216668 CAPLUS
 DOCUMENT NUMBER: 142:297984
 TITLE: Preparation of indole-2-carboxamide derivatives as glycogen phosphorylase inhibitors
 INVENTOR(S): Bennett, Stuart Norman Lile; Simpson, Iain
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020985	A1	20050310	WO 2004-GB3620	20040825
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, U2, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:		GB 2003-20242	A 20030829	
		GB 2004-1800	A 20040128	

OTHER SOURCE(S): MARPAT 142:297984
 GI



AB Title compds. represented by the formula I [wherein A = phenylene or heteroarylene; n = 0-2; m = 0-2; R1 = independently halo, NO2, CN, carbamoyl, etc.; R2R3 = (un)substituted heterocyclic ring; R4 =


L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 independently halo, OH, carboxy, etc.; with a proviso; and pharmaceutically acceptable salts or prodrugs thereof] were prep'd. as glycogen phosphorylase inhibitors (no data). For example, II was given in a multi-step synthesis starting from 5-chloroindole-2-carboxylic acid. I and their pharmaceutical compns. are useful as glycogen phosphorylase inhibitors for the treatment of disease states assocd. with increased glycogen phosphorylase activity (no data).

IT 597555-50-5P 846542-86-7P 847658-36-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of N-indenyl indole-2-carboxamide derivs. as glycogen phosphorylase inhibitors)

RN 597555-50-5 CAPLUS

CN Carbamic acid, [(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 846542-86-7 CAPLUS

CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1H-inden-1-yl]-[(2-tetrahydro-2H-pyran-2-yl)oxy]ethylamino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847658-36-0 CAPLUS

CN Carbamic acid, [(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, (4-nitrophenyl)methyl ester (9CI)


L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 847658-37-1 CAPLUS
 CN Carbamic acid, [(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847658-38-2 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl]-5-chloro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




• HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2005182625 CAPLUS
 DOCUMENT NUMBER: 142:261398
 TITLE: Preparation of indole-2-carboxamide derivatives as glycogen phosphorylase inhibitors
 INVENTOR(S): Bennett, Stuart Norman Lile; Simpson, Iain; Whittamore, Paul Robert Owen
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 74 pp.
 CODEN: PIKXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019172	A1	20050303	WO 2004-GB3552	20040818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, T2, UA, UG, US, U2, VC, VN, YU, ZA, ZM, ZW, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZN, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:		GB 2003-19690	A 20030822	

OTHER SOURCE(S): MARPAT 142:261398
 GI




AB Title compds. represented by the formula I [wherein A = phenylene or heteroarylene; n = 0-2; m = 0-2; R1 = independently halo, NO2, CN,

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 846542-54-9 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-[(2S)-2-(acetylamino)-3-hydroxy-1-oxopropyl]methylamino]-2,3-dihydro-1H-inden-2-yl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846542-55-0 CAPLUS
 CN Pentanediamide,
 N-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-2-hydroxy-N-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 carbamoyl, etc.; R2, R3 = independently (halo)alkyl, CF3, hydroxylalkyl, etc.; R4 = independently halo, OH, carboxy, etc.; and pharmaceutically acceptable salts or prodrugs thereof] were prepd. as glycogen phosphorylase inhibitors. For example, II-HCl was given in a multi-step synthesis starting from 5-chloroindole-2-carboxylic acid. II showed 173 μ M thermodyn. solv. and plasma protein binding activity with Ki value of 0.5 μ M. Thus, I and their pharmaceutical compns. are useful as glycogen phosphorylase inhibitors for the treatment of disease states assocd. with increased glycogen phosphorylase activity.

IT 846542-52-79 846542-53-89 846542-54-9P
 846542-55-0P 846542-56-1P 846542-57-2P
 846542-58-3P 846542-59-4P 846542-60-7P
 846542-61-8P 846542-62-9P 846542-63-0P
 846542-64-1P 846542-65-2P 846542-67-4P
 846542-68-5P 846542-69-6P 846542-70-9P
 846542-71-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indole-2-carboxamide derivs. as glycogen phosphorylase inhibitors)

RN 846542-52-7 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-1-[(2S)-2,3-dihydroxy-1-oxopropyl]methylamino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-53-8 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-[(2S)-2-amino-3-hydroxy-1-oxopropyl]methylamino]-2,3-dihydro-1H-inden-2-yl]-5-chloro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 846542-56-1 CAPLUS
 CN Pentanediamide,
 N-[(1R,2R)-2-[(5-fluoro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-2-hydroxy-N-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-57-2 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[(2S)-2-hydroxy-3-methoxy-1-oxopropyl]methylamino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-58-3 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-2,3-dihydro-1-[(2S)-2-hydroxy-3-methoxy-1-oxopropyl]methylamino]-1H-inden-2-yl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-59-4 CAPLUS
 CN Butanediamide,
 N1-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-2-hydroxy-N1-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-60-7 CAPLUS
 CN Butanediamide,
 N1-[(1R,2R)-2-[(5-fluoro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-2-hydroxy-N1-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-61-8 CAPLUS
 CN Butanediamide,
 N1-[(1R,2R)-2,3-dihydro-2-[(1H-indol-2-yl)carbonyl]amino]-1H-inden-1-yl]-2-hydroxy-N1-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-62-9 CAPLUS
 CN Butanediamide, N1-[(1R,2R)-2,3-dihydro-2-[(5-methyl-1H-indol-2-yl)carbonyl]amino]-1H-inden-1-yl]-2-hydroxy-N1-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-63-0 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-2,3-dihydro-1-[(2S)-2-hydroxy-1-oxobutyl]methylamino]-1H-inden-2-yl]-5-methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-64-1 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-2,3-dihydro-1-[(2S)-2-hydroxy-1-oxobutyl]methylamino]-1H-inden-2-yl]-5-fluoro-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-65-2 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-2,3-dihydro-1-[(2S)-2-hydroxy-1-oxobutyl]methylamino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-67-4 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[(2S)-2-hydroxy-1-oxobutyl]methylamino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-68-5 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-[(2S)-2,3-dihydro-1H-inden-2-yl]-5-methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-69-6 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[(hydroxyacetyl)(2-hydroxyethyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-70-9 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[(2-hydroxyethyl)(2-hydroxyethyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846542-71-0 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-1-[(2R)-2,3-dihydroxy-1-oxopropyl]methylamino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 597555-50-5P 846542-72-1P 846542-73-2P
 846542-74-3P 846542-75-4P 846542-76-5P
 846542-77-6P 846542-78-7P 846542-79-8P
 846542-80-1P 846542-81-2P 846542-82-3P
 846542-83-4P 846542-84-5P 846542-85-6P
 846542-86-7P 846542-87-8P 846542-88-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of indole-2-carboxamide derivs. as glycogen phosphorylase inhibitors)

RN 597555-50-5 CAPLUS


CN Carbamic acid, [(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-72-1 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-1-[[((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)carbonyl]methylamino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846542-73-2 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-(methylamino)-1H-inden-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 846542-74-3 CAPLUS
 CN Carbamic acid, [(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-ylmethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846542-75-4 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-2,3-dihydro-1-(methylamino)-1H-inden-2-yl]-5-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 846542-76-5 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-2,3-dihydro-1-(methylamino)-1H-inden-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 846542-77-6 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-2,3-dihydro-1-(methylamino)-1H-inden-2-yl]-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 846542-78-7 CAPLUS
 CN Carbamic acid, [(1R,2R)-2-[(5-fluoro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-ylmethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-79-8 CAPLUS
 CN Carbamic acid, [(1R,2R)-2,3-dihydro-2-[(1H-indol-2-ylcarbonyl)amino]-1H-inden-1-ylmethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-80-1 CAPLUS
 CN Carbamic acid, [(1R,2R)-2,3-dihydro-2-[(5-methyl-1H-indol-2-yl)carbonyl]amino]-1H-inden-1-ylmethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-81-2 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-(methyltetrahydro-5-oxo-2-furanylcarbonyl)amino]-1H-inden-2-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-82-3 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-2,3-dihydro-1-(methyl[[(2S)-tetrahydro-5-oxo-2-furanyl]carbonyl]amino)-1H-inden-2-yl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-83-4 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-(methyl[(2S)-oxiranecarbonyl]amino)-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-84-5 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-2,3-dihydro-1-[methyl[(2S)-oxiranecarbonyl]amino]-1H-inden-2-yl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846542-85-6 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[(2S)-2-hydroxy-1-oxobutyl]-2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]amino)-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846542-86-7 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[(2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846542-87-8 CAPLUS


L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl]-5-chloro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 597554-85-3

CMF C18 H16 Cl N3 O

Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 846542-88-9 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]methylamino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS FORMAT

ACCESSION NUMBER: 2005-177891 CAPLUS
 DOCUMENT NUMBER: 142:261397

TITLE: Preparation of thieno[2,3-b]pyrrole-5-carboxamide derivatives as glycogen phosphorylase inhibitors

INVENTOR(S): Bennett, Stuart Norman Liles, Simpson, Iain/Whitbeck, Paul Robert Owen

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited

SOURCE: PCT Int. Appl., 84 pp.



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005018637	A1	20050303	WO 2004-GB3546	20040819
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KB, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MZ, NA, NI, NO, N2, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, BW, GH, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, RZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, QQ, GW, MI, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			GB 2003-19759	A 20030822
OTHER SOURCE(S):			MARPAT 142:261397	
GI				



AB Title compds. represented by the formula I [wherein A = phenylene or heteroarylene; n = 0-2; R1 = independently halo, NO2, CN, carbamoyl, etc.];

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 R2, R3 = independently (halo)alkyl, CF₃, hydroxalkyl, etc.; R4R5 = -S-(R6)-(R7)- or -C(R7)-C(R6)S-; R6, R7 = independently H, halo, OH, carboxy, etc., and pharmaceutically acceptable salts or prodrugs thereof. Were prep'd, as glycogen phosphorylase inhibitors. For example, II was given in a multi-step synthesis starting from the reaction of Me 2-chlorothiophene-3-carboxaldehyde with Me azidocetate. II showed plasma-protein binding activity with an IC₅₀ value of 0.07 μ M. Thus, I and their pharmaceutical compns. are useful as glycogen phosphorylase inhibitors for the treatment of disease states assoc'd. with increased glycogen phosphorylase activity.

IT 846545-87-7P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (preparation of thieno[2,3-b]pyrrole-5-carboxamide derivs. as glycogen phosphorylase inhibitors)

RN 846545-87-7 CAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2,3-dihydro-

1-[(2R)-2-hydroxy-3-(methylthio)-1-oxopropyl)methylamino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 846545-67-3P 846545-68-4P 846545-69-5P

846545-70-8P 846545-71-9P 846545-72-0P

846545-73-1P 846545-74-2P 846545-76-4P

846545-77-5P 846545-78-6P 846545-79-7P

846545-81-1P 846545-82-2P 846545-83-3P

846545-84-4P 846545-85-5P 846545-86-6P

846545-88-8P 846545-89-9P 846545-90-2P

846545-91-3P 846545-92-4P 846545-93-5P

846545-94-6P 846545-95-7P 846545-96-8P

846545-97-9P 846545-98-0P 846545-99-1P

846546-00-7P 846546-01-8P 846546-02-9P

846546-03-0P 846546-04-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of thieno[2,3-b]pyrrole-5-carboxamide derivs. as glycogen phosphorylase inhibitors)

RN 846545-67-3 CAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(methoxyacetyl)methylamino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 846545-68-4 CAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(3-hydroxy-2-(hydroxymethyl)-1-oxopropyl)methylamino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 846545-69-5 CAPLUS

CN Propanoic acid, 3-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino-2,3-dihydro-1H-inden-1-yl]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846545-70-8 CAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[(acetoxy)acetyl]methylamino]-2,3-dihydro-1H-inden-2-yl]-2-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 846545-71-9 CAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(hydroxyacetyl)methylamino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 846545-72-0 CAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[(2,3-dihydroxy-1-oxopropyl)methylamino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846545-73-1 CAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[(2S)-2,3-dihydroxy-1-oxopropyl)methylamino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 846545-74-2 CAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[(2R)-2,3-dihydroxy-1-oxopropyl)methylamino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 846545-76-4 CAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(3-hydroxy-1-oxopropyl)methylamino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 846545-77-5 CAPLUS


CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(hydroxyacetyl)(2-hydroxyethyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846545-78-6 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(2R)-2-hydroxy-1-oxopropyl]methylamino]-1H-inden-2-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846545-79-7 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(2S)-2-hydroxy-1-oxopropyl]methylamino]-1H-inden-2-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846545-81-1 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1-[(2R)-2,3-dihydroxy-1-oxopropyl]methylamino]-2,3-dihydro-1H-inden-2-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846545-85-5 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[(2S)-2-hydroxy-1-oxobutyl]methylamino]-1H-inden-2-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846545-86-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[(2S)-2-hydroxy-3-methyl-1-oxobutyl]methylamino]-1H-inden-2-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846545-88-8 CAPLUS
 CN Carbamic acid, (2S)-3-[(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]methylamino]-2-hydroxy-3-




RN 846545-82-2 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1-[(2S)-2,3-dihydroxy-1-oxopropyl]methylamino]-2,3-dihydro-1H-inden-2-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846545-83-3 CAPLUS
 Butanediamide, N1-[(1R,2R)-2-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-2-hydroxy-N1-methyl-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 846545-84-4 CAPLUS
 Butanediamide, N1-[(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-2-hydroxy-N1-methyl-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 846545-89-9 CAPLUS
 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1-[(2S)-3-cyano-2-hydroxy-1-oxopropyl]methylamino]-2,3-dihydro-1H-inden-2-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846545-90-2 CAPLUS
 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[(2S)-2-(acetylamino)-3-hydroxy-1-oxopropyl]methylamino]-2,3-dihydro-1H-inden-2-yl]-2-chloro-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846545-91-3 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[(2S)-2-(acetylamino)-3-hydroxy-1-oxopropyl]methylamino]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846545-92-4 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[(2S)-2-amino-3-hydroxy-1-oxopropyl]methylamino]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl




RN 846545-96-8 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(2R)-2-hydroxy-3-methoxy-1-oxopropyl]methylamino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846545-97-9 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[(2S)-2-hydroxy-3-methoxy-1-oxopropyl]methylamino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 846545-98-0 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-

RN 846545-93-5 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[(2S)-2-amino-3-hydroxy-1-oxopropyl]methylamino]-2,3-dihydro-1H-inden-2-yl]-2-chloro-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 846545-94-6 CAPLUS
 CN Pentanediamide, N1-[(1R,2R)-2-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-2-hydroxy-N1-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846545-95-7 CAPLUS
 CN Pentanediamide, N1-[(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-2-hydroxy-N1-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




1-[(2R)-2-hydroxy-3-(methylsulfonyl)-1-oxopropyl]methylamino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846545-99-1 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[(2S)-3-amino-2-hydroxy-1-oxopropyl]methylamino]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 846546-00-7 CAPLUS
 CN Butanediamide, N1-[(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-2-hydroxy-N1,N4-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846545-98-0 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-




RN 846546-01-8 CAPLUS
 CN Butanediamide, N1-[(1R,2R)-2-[[{(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl}amino]-2,3-dihydro-1H-inden-1-yl]-2-hydroxy-N1,N4,N4-trimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846546-02-9 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[(2,3-dihydroxy-1-oxopropyl)(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846546-03-0 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[(2R)-2,3-dihydroxy-1-oxopropyl)(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)




RN 596847-02-8 CAPLUS
 CN Carbamic acid, [(1R,2R)-2-[[{(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl}amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846546-05-2 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-(methylamino)-1H-inden-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



• HCl


RN 846546-06-3 CAPLUS
 CN Carbamic acid, [(1R,2R)-2-[[{(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl}amino]-2,3-dihydro-1H-inden-1-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846546-04-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[(2S)-2,3-dihydroxy-1-oxopropyl)(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 403860-50-4P 596847-02-8P 846546-05-2P
 846546-06-3P 846546-07-4P 846546-08-5P
 846546-09-6P 846546-10-9P 846546-11-0P
 846546-12-1P 846546-13-2P 846546-14-3P
 846546-15-4P 846546-16-5P 846546-17-6P
 846546-18-7P 846546-19-8P 846546-20-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (preparation of thieno[2,3-b]pyrrole-5-carboxamide derivs. as glycogen phosphorylate inhibitors)


RN 403860-50-4 CAPLUS
 CN Carboxamic acid, [(1R,2R)-2-[[{(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl}amino]-2,3-dihydro-1H-inden-1-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846546-07-4 CAPLUS
 CN Glycine, N-[(acetyl oxy)acetyl]-N-[(1R,2R)-2-[[{(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl}amino]-2,3-dihydro-1H-inden-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846546-08-5 CAPLUS
 CN Glycine, N-[(1R,2R)-2-[[{(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl}amino]-2,3-dihydro-1H-inden-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846546-09-6 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl]-2-chloro-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 846546-10-9 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-(methylamino)-1H-inden-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 846546-11-0 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]methylamino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 846546-12-1 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]methylamino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


RN 846546-15-4 CAPLUS
 CN 4H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-(methyl[(2S)-oxiranylcarbonyl]amino)-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 846546-16-5 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[(methyl[(2S)-oxiranylcarbonyl]amino)-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 846546-17-6 CAPLUS
 CN 4H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[(2,2-dimethyl-1,3-dioxolan-4-yl)carbonyl]2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.





RN 846546-13-2 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-(methyl[(2S)-tetrahydro-5-oxo-2-furanyl]carbonyl)amino)-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846546-14-3 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[(methyl[(2S)-tetrahydro-5-oxo-2-furanyl]carbonyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846546-18-7 CAPLUS
 CN 4H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[(2S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 846546-19-8 CAPLUS
 CN 4H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[(2S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 846546-20-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl)amino]-1H-inden-2-yl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 ACCESSION NUMBER: 2003:719488 CAPLUS
 DOCUMENT NUMBER: 139:26010
 TITLE: Preparation of heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
 INVENTOR(S): Whittamore, Paul Robert Owen; Bennett, Stuart Norman
 Lile; Simpson, Iain
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 131 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074531	A1	20030912	WO 2003-GB875	20030304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW				
CA 2477125	AA	20030912	CA 2003-2477125	20030304
BR 2003008145	A	20041207	BR 2003-8145	20030304
EP 1483271	A1	20041208	EP 2003-743418	20030304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005131052	A1	20050616	US 2003-506746	20030304
JP 2005524669	T2	20050818	JP 2003-572999	20030304
NO 2004004033	A	20041125	NO 2004-4033	20040924
			GB 2002-5170	A 20020306
			WO 2003-GB875	W 20030304

PRIORITY APPLN. INFO.: OTHER SOURCE(S): MARPAT 139:246010
 GI

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Heterocyclic amides of formula I (most examples are N-indenyl 4H-thieno[3,2-b]pyrrole-5-carboxamides, e.g. 2,3-dichloro-N-[(1R*,2R*)-1-(formylamino)-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide (shown as II)) (Z is CH or N; R4 and R5 together are either -SC(R6)-C(R7)- or -C(R7)-C(R6)S-; R6 and R7 = for example H, halo, Cl-4alkyl and Cl-4alkanoyl; A is phenylene or heteroarylene; n is 0, 1 or 2; R1 = for example halo, nitro, cyano, hydroxy, carboxy; r is 1 or 2; Y is -NR2R3 or -OR3; R2 and R3 = for example H, hydroxy, aryl, heterocyclic and Cl-4alkyl; (un)substituted by 1 or 2 R8 groups; R4 = for example H, halo, nitro, cyano, hydroxy, Cl-4alkyl, and Cl-4alkanoyl; R8 = for example hydroxy, -COCOR9, -C(O)N(R9)R10, -NHC(O)R9, (R9)R10N- and -COOR9; R9 and R10 = for example H, hydroxy, Cl-4alkyl (un)substituted by 1 or 2 R13; R13 = hydroxy, halo, trihalomethyl and Cl-4alkoxy) or a pharmaceutically acceptable salt or pro-drug thereof are claimed; they possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity (e.g. type 2 diabetes, insulin resistance, syndrome X, hyperinsulinemia, hyperglucagonemia, cardiac ischemia, obesity). Processes for the manufacture of said heterocyclic amide derivs. and pharmaceutical compns. containing them are described. Inhibitory activity (IC50) of I in the direction of glycogen synthesis and on glycogen degradation

Were measure and are generally 100 μ M to 1 mM; 4.5 μ M for 2,3-dichloro-N-[(1S,2S*)-1-[(3-thienylcarbonyl)amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide in the latter assay. Sixty-four example preps. and/or characterization data for I and 23 for intermediates are included. For example, to prepare 2,3-dichloro-N-[(1R*,2R*)-1-(formylamino)-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide, N-((1R*,2R*)-1-amino-2,3-dihydro-1H-inden-2-yl)-2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide trifluoroacetate (0.5 mmol), formic acid (1.4 mmol), DIPEA (1.0 mmol) and HOBt (0.5 mmol) were

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 and dissolved in CH_2Cl_2 (5 mL), stirred for 5 min, EDCI (0.625 mmol) added and the reaction stirred for 1 h; formic acid (1.4 mmol) and EDCI (1.25 mmol) were added, the reaction stirred for 2 h and the volatiles removed by evapn. under reduced pressure, workup gave 89% of the product as a white foam. The carboxamide reactant was prep'd. (82%) by deprotection of

2,3-dichloro-5-[N-((1R,2R*)-1-[(1-(1-dimethylethoxy)carbonyl)amino]indan-3-ylcarbamoyl)-4H-thieno[3,2-b]pyrrole using trifluoroacetic acid and this reactant was prep'd. (80%) from 5-carboxy-2,3-dichloro-4H-thieno[3,2-b]pyrrole (prepn. given) and trans-2-amino-1-[(1,1-dimethylethoxy)carbonyl]indan (prepn. given) using DIPEA, HOBt in CH_2Cl_2 followed by EDCI.

IT 596845-92-0P, N-[(1S,2S)-1-[(1R)-3-[(tert-Butoxycarbonyl)amino]-3-carbamoylpropanyl]amino]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-4H-

2,3-dichloro-N-[(1R,2R)-1-[(4R)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596845-95-3P, N-[(1R,2R)-1-[(2-Acetoxyacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-22-99, N-[(1R,2R)-1-[(2-Amino-2-oxoethyl)amino]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-37-69,


N-[(1R,2R)-1-[(2-Acetoxyacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro-6H-thieno[2,3-b]pyrrole-5-carboxamide 596846-41-29, N-[(1S,2S)-1-[(2S)-2-((tert-Butoxycarbonyl)amino)-2-carbamoylacyl]amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro-6H-thieno[2,3-b]pyrrole-5-carboxamide 596846-44-59, N-[(1S,2S)-1-[(tert-Butoxycarbonyl)amino]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-72-99,

RL: PAC (Pharmacological activity); RCT (Reagent); SPT (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reagent or reagent); USES (Uses); DRUG (Drug candidate; preparation of heterocyclic amide derivs. having glycogen phosphorylase inhibitory activity)

RN 596845-92-0 CAPLUS


CN Carbamic acid, [(1R)-1-(aminocarbonyl)-3-[(1S,2S)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596845-93-1 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1-[(4R)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596845-95-3 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[(acetoxyacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-22-9 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[(2-amino-2-oxoethyl)amino]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-44-5 CAPLUS
 CN Carbamic acid, [2-[(1S,2S)-2-[(2-chloro-6H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-72-9 CAPLUS
 CN Glycine, N-[(1R,2R)-2-[(2-chloro-6H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 403860-03-7P, 2,3-Dichloro-N-[(1R,2R)-1-[(methylsulfonyl)amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide

Absolute stereochemistry.




RN 596846-23-0 CAPLUS
 CN Glycine, N-[(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 596846-37-6 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[(acetoxyacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 596846-41-2 CAPLUS
 CN Carbamic acid, [(1S)-1-(aminocarbonyl)-2-[(1S,2S)-2-[(2-chloro-6H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

2,3-Dichloro-N-[(1R,2R)-1-[(methoxyacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596845-94-2P,

2,3-Dichloro-N-[(1R,2R)-1-[(3-methoxypropanoyl)amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596845-96-4P,
 N-[(1R,2R)-1-[(2-Carbamoylacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide 596845-97-5P,

2,3-Dichloro-N-[(1R,2R)-1-[(trifluoromethyl)amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596845-99-7P,
 2,3-Dichloro-N-[(1S,2S)-1-[(furan-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-00-3P,
 2,3-Dichloro-N-[(1S,2S)-1-[(furan-3-yl)carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-03-4P,
 2,3-Dichloro-N-[(1S,2S)-1-[(2-thienyl)carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-02-5P,

2,3-Dichloro-N-[(1S,2S)-1-[(5-nitrofuran-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-03-6P

2,3-Dichloro-N-[(1S,2S)-1-[(pyridin-3-yl)carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-04-7P,
 N-[(1S,2S)-1-[(Acetylaminocarbonyl)amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-05-8P
 596846-06-9P, N-[(1S,2S)-1-[(Acetylaminocarbonyl)amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide
 596846-07-0P, N-[(1S,2S)-1-[(2-Carboxyacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide
 596846-08-1P, 2,3-Dichloro-N-[(1S,2S)-1-[(2-Carboxyacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide

[(dimethylamino)carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-09-2P, 596846-11-6P,
 2,3-Dichloro-N-[(1S,2S)-1-[(ethylamino)carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-12-7P,
 2,3-Dichloro-N-[(1S,2S)-1-[(prop-2-en-1-ylamino)carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide
 596846-13-8P, 2,3-Dichloro-N-[(1S,2S)-1-[(3,5-dinitrophenyl)amino]carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-14-9P,
 2,3-Dichloro-N-[(1S,2S)-1-[(pyrrolin-2-yl)amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-15-0P,
 N-[(1R,2R)-1-[(3R)-3-Amino-3-carbamoylpropanoyl]amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide
 596846-16-1P, N-[(1R,2R)-1-[(3R)-3-Carboxy-3-hydroxypropanoyl]amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide
 596846-17-2P, 2,3-Dichloro-N-[(1R,2R)-1-[(hydroxyacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-18-3P,
 2,3-Dichloro-N-[(1S,2S)-1-[(methylsulfonyl)amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-20-7P,

2,3-Dichloro-N-[(1S,2S)-1-[(methyl(morpholin-4-ylacetyl)amino)-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-24-1P,
 N-[(1R,2R)-1-[(Carboxymethyl)amino]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-25-2P,

N-[(1R,2R)-1-[N-Acetyl-N-(carboxymethyl)amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-26-3P

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-27-4P,
 N-[(1R,2R)-1-[(Acetyl)(2-amino-2-oxoethyl)amino]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide
 596846-28-5P, N-[(1R,2R)-1-[(Carboxymethyl)-N-(hydroxycetyl)amino]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-30-9P,
 2-Chloro-N-[(1R,2R)-1-[(2S)-5-oxotetrahydrofuran-2-yl]carbonyl]amino]-2,3-dihydro-1H-inden-2-yl)-6H-thieno[2,3-b]pyrrole-5-carboxamide
 596846-32-1P 596846-33-2P, 2-Chloro-N-[(1R,2R)-1-


{(methoxycetyl)amino]-2,3-dihydro-1H-inden-2-yl]-6H-thieno[2,3-b]pyrrole-5-carboxamide 596846-34-3P, N-[(1R,2R)-1-(Acetyl)amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro-6H-thieno[2,3-b]pyrrole-5-carboxamide 596846-35-4P, 2-Chloro-N-[(1R,2R)-1-[(3-methoxypropanoyl)amino]-2,3-dihydro-1H-inden-2-yl]-6H-thieno[2,3-b]pyrrole-5-carboxamide 596846-46-7P, N-[(1R,2R)-1-[(2-Carbamoylacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro-6H-thieno[2,3-b]pyrrole-5-carboxamide
 596846-48-9P, N-[(1R,2R)-1-[(2-tert-Butoxycarbonyl)acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro-6H-thieno[2,3-b]pyrrole-5-carboxamide 596846-49-0P, 2-Chloro-N-[(1R,2R)-1-[(3-hydroxy-2-(hydroxymethyl)propanoyl)amino]-2,3-dihydro-1H-inden-2-yl]-6H-thieno[2,3-b]pyrrole-5-carboxamide 596846-51-4P, N-[(1R,2R)-1-[(3R)-3-Amino-3-carbamoylpropanoyl)amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro-6H-thieno[2,3-b]pyrrole-5-carboxamide trifluoroacetate 596846-54-7P
 N-[(1R,2R)-1-[(Aminocetyl)amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro-6H-thieno[2,3-b]pyrrole-5-carboxamide trifluoroacetate 596846-56-9P
 2-Chloro-N-[(1R,2R)-1-[(2-hydroxyethyl)(phenylmethyl)amino]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-6H-thieno[2,3-b]pyrrole-5-carboxamide 596846-59-2P, 2-Chloro-N-[(1R,2R)-1-[(3-methoxy-4-acetyl)amino]-2,3-dihydro-1H-inden-2-yl]-6H-thieno[2,3-b]pyrrole-5-carboxamide
 596846-60-5P, 2-Chloro-N-[(1R,2R)-1-[(2-hydroxyethyl)(methyl)amino]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-6H-thieno[2,3-b]pyrrole-5-carboxamide 596846-61-6P, N-[(1R,2R)-1-[(Bis[2-hydroxyethyl]amino)acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro-6H-thieno[2,3-b]pyrrole-5-carboxamide
 596846-63-8P, 2-Chloro-N-[(1R,2R)-1-[(ethyl)-2-hydroxyethyl]amino]-2,3-dihydro-1H-inden-2-yl]-6H-thieno[2,3-b]pyrrole-5-carboxamide 596846-64-9P, 2-Chloro-N-[(1R,2R)-1-

[(2,3-dihydroxypropyl)(methyl)amino]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-6H-thieno[2,3-b]pyrrole-5-carboxamide 596846-66-1P, N-[(1R,2R)-1-[(Bis[2-hydroxypropyl]amino)acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro-6H-thieno[2,3-b]pyrrole-5-carboxamide
 596846-68-3P, N-[(1R,2R)-1-[(2-Amino-2-oxoethyl)amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro-6H-thieno[2,3-b]pyrrole-5-carboxamide 596846-75-2P, N-[(1R,2R)-1-[(Carboxymethyl)amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro-6H-thieno[2,3-b]pyrrole-5-carboxamide trifluoroacetate 596846-77-4P, 2-Chloro-N-[(1R,2R)-1-

{(hydroxycetyl)amino]-2,3-dihydro-1H-inden-2-yl]-6H-thieno[2,3-b]pyrrole-5-carboxamide 596846-79-6P, 2,3-Dichloro-N-[(1R,2R)-1-


{(chloroacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-81-0P, N-[(1R,2R)-1-[(3S)-3-Amino-3-carboxypropanoyl)amino]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-85-4P, N-[(1R,2R)-1-[(2-Carboxyacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-2,3-

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 596845-94-2 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide,
 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[(3-methoxy-1-oxopropyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 596845-96-4 CAPLUS
 CN Propanediamide, N-[(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 596845-97-5 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide,
 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[(trifluoroacetyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-88-7P,
 N-[(1R,2R)-1-[(2-Carboxyacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro-6H-thieno[3,2-b]pyrrole-5-carboxamide 596846-91-2P,
 N-[(1R,2R)-1-[(2S)-3-Amino-3-carboxypropanoyl)amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro-6H-thieno[3,2-b]pyrrole-5-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of heterocyclic amide derivs. having glycogen phosphorylase inhibitory activity)

RN 403860-03-7 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide,
 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[(methylsulfonyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 596845-89-5 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(formylamino)-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 596845-91-9 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide,
 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[(methoxyacetyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 596845-94-2 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1S,2S)-1-[(2-

furanylcarbonyl)amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 596845-99-7 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1S,2S)-1-[(3-furanylcarbonyl)amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 596846-00-3 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1S,2S)-1-[(3-furanylcarbonyl)amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-01-4 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide,
 2,3-dichloro-N-[(1S,2S)-2,3-dihydro-1-[(2-thienylcarbonyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.



RN 596846-02-5 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1S,2S)-2,3-dihydro-1-[(5-nitro-2-furyl)carbonyl]amino]-1H-inden-2-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-03-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1S,2S)-2,3-dihydro-1-[(3-pyridinylcarbonyl)amino]-1H-inden-2-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1S,2S)-1-(acetylamino)-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-07-0 CAPLUS
 CN Propanoic acid, 3-[(1S,2S)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-08-1 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1S,2S)-1-[(dimethylamino)carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-09-2 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1S,2S)-1-[(4-methyl-1-piperazinyl)carbonyl]amino]-1H-inden-2-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-04-7 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1S,2S)-2,3-dihydro-1-[(1-oxo-2-propenyl)amino]-1H-inden-2-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-05-8 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1S,2S)-2,3-dihydro-1-[(3-hydroxybenzoyl)amino]-1H-inden-2-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-06-9 CAPLUS




RN 596846-11-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1S,2S)-1-[(ethylamino)carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 596846-12-7 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1S,2S)-2,3-dihydro-1-[(2-propenylamino)carbonyl]amino]-1H-inden-2-yl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 596846-13-8 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1S,2S)-1-[(3,5-


L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 596846-14-9 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1S,2S)-1-(formylamino)-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-15-0 CAPLUS
 CN Butanediamide, 2-amino-N4-[(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, (2R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 607725-18-8
 CMF C20 H19 Cl2 N5 O3 S

Absolute stereochemistry.




L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 596846-20-7 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1S,2S)-2,3-dihydro-1-(methyl(4-morpholinylacetyl)amino)-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 596846-24-1 CAPLUS
 CN Glycine, N-[(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 596846-25-2 CAPLUS
 CN Glycine, N-acetyl-N-[(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 596846-16-1 CAPLUS
 CN Butanoic acid, 4-[(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]-2-hydroxy-4-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 596846-17-2 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[(hydroxyacetyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 596846-18-3 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1S,2S)-2,3-dihydro-1-[(methylsulfonyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 596846-27-4 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-(acetyl(2-amino-2-oxoethyl)amino)-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-28-5 CAPLUS
 CN Glycine, N-[(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-N-(hydroxyacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-30-9 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(2S)-tetrahydro-5-oxo-2-furanyl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-32-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-(formylamino)-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-33-2 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(methoxyacetyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-34-3 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-(acetylamino)-2,3-dihydro-1H-inden-2-yl]-2-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-35-4 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(3-methoxy-1-oxopropyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-46-7 CAPLUS
 CN Propanediamide, N-[(1R,2R)-2-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-48-9 CAPLUS
 CN Propanoic acid, 3-[(1R,2R)-2-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]-3-oxo-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 596846-49-0 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(3-hydroxy-2-(hydroxymethyl)-1-oxopropyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-51-4 CAPLUS
 CN Butanediamide, 2-amino-N4-[(1R,2R)-2-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, (2R)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 596846-50-3
 CMF C20 H20 Cl N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 596846-54-7 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[(aminosacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 596846-53-6
 CMF C18 H17 Cl N4 O2 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 596846-56-9 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(2-hydroxyethyl)(phenylmethyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-59-2 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(4-morpholinylacetyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-60-5 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(4-hydroxyethyl)amino]acetyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-61-6 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[(bis(2-hydroxyethyl)amino)acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-63-8 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[(ethyl(2-hydroxyethyl)amino)acetyl]amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-64-9 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[(2,3-dihydroxypropyl)methylamino]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-66-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[(bis(2-hydroxypropyl)amino)acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 596846-68-3 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[(2-amino-2-oxoethyl)amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-75-2 CAPLUS
 CN Glycine, N-[(1R,2R)-2-[(2-chloro-6H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 596846-74-1
 CMF C18 H16 Cl N3 O3 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 596846-77-4 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(hydroxyacetyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-79-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1-[(chloroacetyl)amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-81-0 CAPLUS
 CN L-Asparagine, N-[(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-85-4 CAPLUS
 CN Propanoic acid, 3-[(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 596846-88-7 CAPLUS
 CN Propanoic acid, 3-[(1R,2R)-2-[(2-chloro-6H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-91-2 CAPLUS
 CN L-Asparagine, N-[(1R,2R)-2-[(2-chloro-6H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 tert-Buyl [(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]carbamate
 596845-90-8P, N-[(1R,2R)-1-Amino-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide trifluoroacetate
 596845-99-6P, N-[(1R,2S)-1-Amino-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide 596846-21-8P
 2,3-Dichloro-N-[(1R,2R)-1-(chloroacetyl)(methyl)amino]-2,3-dihydro-1H-inden-2-yl-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]carbamate 596846-26-3P
 1,1-Dimethylethyl 2-(acetyl)[(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]acetic acid 596846-31-0P, N-[(1R,2R)-1-Amino-2,3-dihydro-1H-inden-2-yl]-2-chloro-4H-thieno[3,2-b]pyrrole-5-carboxamide
 596846-58-1P, 2-Chloro-N-[(1R,2R)-1-(chloroacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-2-chloro-4H-thieno[3,2-b]pyrrole-5-carboxamide
 596846-70-7P, N-[(1R,2R)-1-Amino-2,3-dihydro-1H-inden-2-yl]-2-chloro-4H-thieno[3,2-b]pyrrole-5-carboxamide trifluoroacetate
 596847-01-7P, 1,1-Dimethylethyl 2-[(acetyl oxy)acetyl][(1R,2R)-2-
 (((2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl)amino)-2,3-dihydro-1H-inden-1-yl]acetate 596847-02-0P, tert-Butyl
 [(1R,2R)-2-[(2-Chloro-6H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]carbamate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (prepr. of heterocyclic amide derivs. having glycogen phosphorylase inhibitory activity)


RN 403860-99-4 CAPLUS
 CN Carbamic acid, [(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403860-00-4 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 596846-10-5, N-[(1S,2S)-1-Amino-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide trifluoroacetate
 RL: RCT (Reactant); RACT (Reactant or reagent); (preparation of heterocyclic amide derivs. having glycogen phosphorylase inhibitory activity)

RN 596846-10-5 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1S,2S)-1-amino-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 596845-98-6
 CMF C16 H13 Cl2 N3 O S

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




IT 403859-99-4P, 2,3-Dichloro-5-[N-[(1R,2R)-1-(N-(dimethylthioethyl)carbonyl)amino]indan-2-yl]carbamoyl]-4H-thieno[3,2-b]pyrrole 403860-00-4P, N-[(1R,2R)-1-Amino-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide 403860-04-8P, 2,3-Dichloro-N-[(1R,2R)-1-(methylamino)-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide 403860-50-4P




RN 403860-04-8 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-(methylamino)-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403860-50-4 CAPLUS
 CN Carbamic acid, [(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596845-90-8 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 403860-00-4
 CMF C16 H13 Cl2 N3 O S

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 596845-98-6 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1S,2S)-1-amino-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-21-8 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1-[(chloroacetyl)methylamino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.



RN 596846-70-7 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl]-2-chloro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 596846-31-0
CMF C16 H14 Cl N3 O S

Absolute stereochemistry.



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 596847-01-7 CAPLUS
CN Glycine,
N-[(acetoxy)acetyl]-N-[(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 596846-26-3 CAPLUS
CN Glycine, N-[(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-29-6 CAPLUS
CN Glycine,
N-[(acetoxy)acetyl]-N-[(1R,2R)-2-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-31-0 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl]-2-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596846-58-1 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[(chloroacetyl)amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 596847-02-8 CAPLUS
CN Carbamic acid, [(1R,2R)-2-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003-719447 CAPLUS
 DOCUMENT NUMBER: 139-245895
 TITLE: Preparation of indolamide derivatives that possess glycogen phosphorylase inhibitory activity
 INVENTOR(S): Whittamore, Paul Robert Owen; Bennett, Stuart Norman
 Lile; Simpson, Iain
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 90 pp.
 CODEN: PIKXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074484	A1	20030912	WO 2003-GB883	20030304
W: AE, AG, AL, AM, AT, AU, A2, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, RW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2477717	RA	20030912	CA 2003-2477717	20030304
BR 2003008144	A	20041207	BR 2003-8144	20030304
EP 1483240	A1	20041208	EP 2003-712310	20030304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005107362	A1	20050519	US2003-5065547	20030304
JP 2005524667	T2	20050818	JP 2003-572954	20030304
NO 2004004032	A	20041005	NO 2004-4032	20040924
			GB 2002-5176	A 20020306
PRIORITY APPLN. INFO.:				
			WO 2003-GB883	W 20030304

OTHER SOURCE(S): MARPAT 139:245895
 GI




AB Heterocyclic amides of formula (I): 5-chloro-2-(N-(1-hydroxyindan-2-yl)carbamoyl)indole; A is phenylene or heteroarylene; m is 0, 1 or 2; n is 0, 1 or 2; R1 = for example halo, nitro, cyano, hydroxy, carboxy; r is 1 or 2; Y is -NR2R3 or -OR3; R2 and R3 = for example H, hydroxy, aryl, heterocyclyl and Cl-4 alkyl((un)substituted by 1 or 2 R8 groups); R4 = for

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 597554-91-1 CAPLUS
 CN Carboxanic acid, [(1S)-1-acetyl-3-[(1R,2R)-2-[(5-chloro-1H-inden-2-yl)carbamoyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597555-23-2 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[1-[(cyanomethyl)amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 597555-25-4 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-[(2-amino-2-oxoethyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 example H, halo, nitro, cyano, hydroxy, Cl-4 alkyl, and Cl-4 alkanoyl; R8 = for example hydroxy, -COCO9, -C(O)N(R9)(R10), -NHC(R10)R9, and -COOR9; R9 and R10 = for example H, hydroxy, Cl-4 alkyl((un)substituted by 1 or 2 R13); R13 = hydroxy, halo, trihalomethyl and Cl-4 alkoxyl or a pharmaceutically acceptable salt or prodng thereof are claimed. They possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states assocd. with increased glycogen phosphorylase activity, e.g. type 2 diabetes, insulin resistance, syndrome X, hyperinsulinemia, hyperglucagonemia, cardiac ischemia, obesity. Inhibitory activity (IC50) of I in the direction of glycogen synthesis and on glycogen degrdn. were measure and are generally 100 μ M to 1 nM; 7.4 μ M for 5-chloro-N-[(1R,2R)-1-[(2-

hydroxyethyl)(phenylmethyl)amino]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide in the latter assay. Processed for the manuf. of said heterocyclic amide derivs. and pharmaceutical compns. contng. them

are described. Thirty-seven example preps. and/or characterization data for I and 11 for intermediates are included. For example, to prep. 5-chloro-2-(N-(trans-1-hydroxyindan-2-yl)carbamoyl)indole, 5-chloro-1H-indole-2-carboxylic acid (0.67 mmol) was dissolved in CH2Cl2 (10 mL) contg. DIPEA (1.19 mmol) and trans-2-aminodan-1-ol (0.67 mmol) and HATU (0.67 mmol); the reaction mixt. was stirred at room temp. for apprx. 18 h; workup gave 100 % of the desired compnd. To prep. trans-2-aminodan-1-ol, isomeric nitrite (108 mmol) was added to a soln. of indan-1,2-dione (90 mmol) in MeOH (300 mL) at 45° followed by concd. HCl (12 mL) dropwise over 5 min; the reaction mixt. was stirred

for 3 h at room temp.; Workup gave indan-1,2-dione-2-oxime (43%), which (39 mmol) in EtOH (470 mL) and 4M HCl/dioxane (36 mL) was hydrogenated at

room temp. and 40 psi; workup gave 86 % of the trans-2-aminodan-1-ol.

IT 597554-89-7P, 5-Chloro-N-[(1R,2R)-1-(tert-butoxycarbonyl)amino]carbamoyl-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597554-91-1P, N-[(1R,2R)-1-[(tert-Butoxycarbonyl)amino]-2-(oxepantanoyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro-1H-indole-2-carboxamide 597555-23-2P,

5-Chloro-N-[(1-[(cyanomethyl)amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-

carboxamide 597555-25-4P, N-[(1R,2R)-1-[(2-Amino-2-oxoethyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro-1H-indole-2-carboxamide 597555-37-8P, N-[(1R,2R)-1-[(2-Acetoxyacetyl)-N-(carboxymethyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloroindole-2-carboxamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(drug candidate; preparation of indolamide derivs. that possess glycogen phosphorylase inhibitory activity)

RN 597554-89-7 CAPLUS

CN Carboxamic acid, [(2-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 597555-37-8 CAPLUS
 CN Glycine, N-[(acetoxy)acetyl]-N-[(1R,2R)-2-[(5-chloro-1H-inden-2-yl)carbamoyl]amino]-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 597554-72-8P, 5-Chloro-2-[N-(trans-1-hydroxyindan-2-yl)carbamoyl]indole 597554-73-1P, 5-Chloro-N-[(1R,2R)-1-

[(methylsulfonyl)amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597554-79-5P, N-[(1R,2R)-1-[(2-Carboxyacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloroindole-2-carboxamide 597554-83-1P,

5-Chloro-N-[(1R,2R)-1-[(3-methoxypropanoyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloroindole-2-carboxamide 597554-93-3P, N-[(1R,2R)-1-[(2-Acetylaminol)-2,3-dihydro-1H-inden-2-yl]-5-chloro-1H-indole-2-carboxamide 597554-93-3P, N-[(1R,2R)-1-[(2-Carbamoylacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloroindole-2-carboxamide 597554-97-7P, 5-Chloro-N-[(1R,2R)-1-[(hydroxyacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597554-98-8P, 5-Chloro-N-[(1R,2R)-1-[(3-hydroxy-2-(hydroxymethyl)propanoyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloroindole-2-carboxamide 597555-01-5P, N-[(1R,2R)-1-[(3R)-3-Amino-2-carboxypropyl]amino]-2,3-dihydro-1H-inden-2-yl]-5-chloroindole-2-carboxamide trifluoroacetate 597555-02-7P 597555-03-0P

N-[(1R,2R)-1-[(Aminoacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro-1H-indole-2-carboxamide trifluoroacetate 597555-05-0P, 5-Chloro-N-[(1S)-1-[(methylsulfonyl)amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597555-08-3P, 5-Chloro-N-[(1H-Inden-2-yl)-1-[(hydroxyacetyl)amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597555-11-0P, 5-Chloro-N-[(1R,2R)-1-[(2-

hydroxyethyl)(phenylmethyl)amino]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide

597555-11-0P, 5-Chloro-N-[(1R,2R)-1-[(2-


hydroxyethyl)(phenylmethyl)amino]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide

597555-11-0P, 5-Chloro-N-[(1R,2R)-1-[(2-

hydroxyethyl)(phenylmethyl)amino]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 hydroxyethyl(methylamino)acetyl)amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597555-12-0P, 5-Chloro-N-[(1R,2R)-1-[(3-hydroxyethyl)phenylmethyl]amino]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597555-13-0P, 5-Chloro-N-[(1R,2R)-1-[(3-hydroxypiperidin-1-yl)acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597555-14-1P, 5-Chloro-N-[(1R,2R)-1-[(3-hydroxypyrrolidin-1-yl)acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597555-15-2P, N-[(1R,2R)-1-[(Bis(2-hydroxyethyl)amino)acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro-1H-indole-2-carboxamide 597555-18-5P, N-[(1-[(Aminocetyl)amino]-2,3-dihydro-1H-inden-2-yl)-5-chloro-1H-indole-2-carboxamide 597555-19-6P, N-[(1-[(3S)-3-Amino-3-carboxypropanoyl]amino]-2,3-dihydro-1H-inden-2-yl)-5-chloro-1H-indole-2-carboxamide 597555-20-9P, 5-Chloro-N-[(1R,2R)-1-[(choloromethyl)sulfonyl]amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597555-22-1P, 5-Chloro-N-[(1-[(trifluoromethyl)sulfonyl]amino)-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597555-26-5P, N-[(1-[(Carboxymethyl)amino]-2,3-dihydro-1H-inden-2-yl)-5-chloroindole-2-carboxamide 597555-28-7P, N-[(1S,2S)-1-(Acetyl)-2-(thienyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloroindole-2-carboxamide 597555-30-1P, N-[(1S,2S)-1-(Acetyl)-N-(carboxymethyl)amino]-2,3-dihydro-1H-inden-2-yl)-5-chloroindole-2-carboxamide 597555-31-2P, N-[(1S,2S)-1-(Acetyl)-N-[(2-(ethoxycarbonyl)cycloprop-1-yl)methyl]amino]-2,3-dihydro-1H-inden-2-yl)-5-chloroindole-2-carboxamide 597555-32-3P, N-[(1R,2R)-1-(N-Acetyl)-N-(carboxymethyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloroindole-2-carboxamide 597555-34-5P, N-[(1R,2R)-1-(Bis(carboxymethyl)amino)-2,3-dihydro-1H-inden-2-yl]-5-chloroindole-2-carboxamide 597555-35-6P, N-[(1R,2R)-1-(Acetyl)-2-(oxoethyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro-1H-indole-2-carboxamide 597555-43-6P, 5-Chloro-N-[(1R,2R)-1-[(2R)-2,3-dihydroxypropyl]amino]-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597555-61-0P, 5-Chloro-2-(N-(1-hydroxyindan-2-yl)carbamoyl)indole
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of indoleamide derivs. that possess glycogen phosphorylase inhibitory activity)
 RN 597554-72-8 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-hydroxy-1H-inden-2-yl], rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 597554-93-3 CAPLUS
 CN Propanediamide,
 N-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597554-95-5 CAPLUS
 CN Propanoic acid, 3-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597554-97-7 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-(hydroxymethyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 597554-75-1 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-(methylsulfonyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597554-79-5 CAPLUS
 CN Propanoic acid, 3-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-3-oxo-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 597554-83-1 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-(3-methoxy-1-oxopropyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597554-87-5 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-(acetylamino)-2,3-dihydro-1H-inden-2-yl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 597554-98-8 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[(3-hydroxymethyl)-1-oxopropyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597555-00-5 CAPLUS
 CN Butanediamide, 2-amino-N4-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597555-01-6 CAPLUS
 CN Butanediamide, 2-amino-N4-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, (2R)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 597555-00-5
 CMF C22 H22 Cl N5 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 597555-02-7 CAPLUS
CN 1H-Indole-2-carboxamide,
N-[(1R,2R)-1-[(aminoacetyl)amino]-2,3-dihydro-1H-
inden-2-yl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-03-8 CAPLUS
CN 1H-Indole-2-carboxamide,
N-[(1R,2R)-1-[(aminoacetyl)amino]-2,3-dihydro-1H-
inden-2-yl]-5-chloro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 597555-02-7
CMF C20 H19 Cl N4 O2

Absolute stereochemistry.




RN 597555-11-8 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[(2-
hydroxyethyl)methylamino]acetyl]amino-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-12-9 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-[(2-
hydroxyethyl)(phenylmethyl)amino]acetyl]amino-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597555-13-0 CAPLUS
CN 1H-Indole-2-carboxamide,
5-chloro-N-[(1R,2R)-2,3-dihydro-1-[(3-hydroxy-1-
piperidinyl)acetyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 597555-05-0 CAPLUS
CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1S,2S)-2,3-dihydro-1-
[(methylsulfonyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-08-3 CAPLUS
CN 1H-Indole-2-carboxamide,
5-chloro-N-[(2,3-dihydro-1-[(hydroxyacetyl)amino]-
1H-inden-2-yl]- (9CI) (CA INDEX NAME)




RN 597555-14-1 CAPLUS
CN 1H-Indole-2-carboxamide,
5-chloro-N-[(1R,2R)-2,3-dihydro-1-[(3-hydroxy-1-
pyrrolidinyl)acetyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-15-2 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-[(bis(2-
hydroxyethyl)amino)acetyl]amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-18-5 CAPLUS
CN 1H-Indole-2-carboxamide,
N-[(1-[(aminoacetyl)amino]-2,3-dihydro-1H-inden-2-
yl]-5-chloro- (9CI) (CA INDEX NAME)




RN 597555-19-6 CAPLUS
 CN L-Asparagine, N-[2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-20-9 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-22-1 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[2,3-dihydro-1-[(trifluoromethyl)sulfonyl]amino]-1H-inden-2-yl- (9CI) (CA INDEX NAME)




RN 597555-24-3 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-2,3-dihydro-1-(1H-tetrazol-5-ylmethyl)amino]-1H-inden-2-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-26-5 CAPLUS
 CN Glycine, N-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-28-7 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1S,2S)-1-[acetyl(2-thienylmethyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-30-1 CAPLUS
 CN Glycine, N-acetyl-N-[(1S,2S)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-31-2 CAPLUS
 CN Cyclopropanecarboxylic acid, 2-[(acetyl(1S,2S)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino)-2,3-dihydro-1H-inden-1-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-32-3 CAPLUS
 CN Glycine, N-acetyl-N-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-34-5 CAPLUS
 CN Glycine, N-(carboxymethyl)-N-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-35-6 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1R,2R)-1-[acetyl(2-amino-2-oxoethyl)amino]-2,3-dihydro-1H-inden-2-yl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-43-6 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-1-[(2R)-2,3-dihydroxypropyl]amino]-2,3-dihydro-1H-inden-2-yl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597555-61-8 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-(2,3-dihydro-1-hydroxy-1H-inden-2-yl)- (9CI) (CA INDEX NAME)




IT 597554-91-9P, N-(trans-1-Amino-2,3-dihydro-1H-inden-2-yl)-5-chloro-1H-indole-2-carboxamide 597554-85-3P, N-((1R,2R)-1-Amino-2,3-dihydro-1H-inden-2-yl)-5-chloro-1H-indole-2-carboxamide 597555-09-4P, 5-Chloro-N-[(1-(iodoacetyl)amino)-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597555-10-7P,
 5-Chloro-N-[(1R,2R)-1-((chloroacetyl)amino)-2,3-dihydro-1H-inden-2-yl]-1H-indole-2-carboxamide 597555-17-4P, N-(1-Amino-2,3-dihydro-1H-inden-2-yl)-5-chloro-1H-indole-2-carboxamide trifluoroacetate 597555-21-0P, N-((1R,2R)-1-Amino-2,3-dihydro-1H-inden-2-yl)-5-chloro-1H-indole-2-carboxamide trifluoroacetate 597555-27-6P,
 1,1-Dimethylthethyl 2-[[1R,2R]-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]acetate 597555-33-4P, N-((1R,2S)-1-Amino-2,3-dihydro-1H-inden-2-yl)-5-chloro-1H-indole-2-carboxamide 597555-33-4P, 1,1-Dimethylthethyl 2-(acetyl((1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino)-2,3-dihydro-1H-inden-1-yl)amino]acetate 597555-39-0P, 1,1-Dimethylthethyl 2-[[1R,2R]-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]amino]acetate 597555-46-9P,
 5-Chloro-2-[N-[(1-(1,1-dimethylthoxy)carbonyl)amino]indan-2-yl]carbamoyl]indole 597555-50-5P, tert-Butyl 2-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]carbamate 597555-53-8P, tert-Butyl 2-[(1S,2S)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]carbamate 597555-59-4P, 597556-42-8P, N-((1S,2S)-1-Amino-2,3-dihydro-1H-inden-2-yl)-5-chloro-1H-indole-2-carboxamide trifluoroacetate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of indolamine derivs. that possess glycogen phosphorylase inhibitory activity)



RN 597555-17-4 CAPLUS
 CN 1H-Indole-2-carboxamide, N-(1-amino-2,3-dihydro-1H-inden-2-yl)-5-chloro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 597555-16-3
 CMF C18 H16 Cl N3 O

CM 2

CRN 76-05-1
 CMF C2 H F3 O2

RN 597555-21-0 CAPLUS
 CN 1H-Indole-2-carboxamide, N-((1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl)-5-chloro-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 597554-85-3
 CMF C18 H16 Cl N3 O

Absolute stereochemistry.


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 597554-81-9 CAPLUS
 CN 1H-Indole-2-carboxamide, N-((1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl)-5-chloro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 597554-85-3 CAPLUS
 CN 1H-Indole-2-carboxamide, N-((1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl)-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-09-4 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1-(iodoacetyl)amino)-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 597555-10-7 CAPLUS
 CN 1H-Indole-2-carboxamide, 5-chloro-N-[(1R,2R)-1-((chloroacetyl)amino)-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2


RN 597555-27-6 CAPLUS
 CN Glycine, N-((1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino)-2,3-dihydro-1H-inden-1-yl)-, 1,1-dimethylthethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-29-8 CAPLUS
 CN 1H-Indole-2-carboxamide, N-((1S,2S)-1-amino-2,3-dihydro-1H-inden-2-yl)-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 597555-33-4 CAPLUS
 CN Glycine, N-acetyl-N-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-39-0 CAPLUS
 CN Glycine, N-[(acetoxy)acetyl]-N-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597555-46-9 CAPLUS
 CN Carbamic acid, [2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 597555-50-5 CAPLUS
 CN Carbamic acid, [(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 Absolute stereochemistry.




RN 597555-53-8 CAPLUS
 CN Carbamic acid, [(1S,2S)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597555-59-4 CAPLUS
 CN Glycine, N-[(1R,2R)-2-[(5-chloro-1H-indol-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-N-(2-(1,1-dimethylethoxy)-2-oxoethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597556-42-8 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1S,2S)-1-amino-2,3-dihydro-1H-inden-2-yl]-5-chloro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CNR 597555-29-8
 CMF C18 H16 Cl N3 O

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002185126 CAPLUS
 DOCUMENT NUMBER: 136:247485
 TITLE: Preparation of bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
 INVENTOR(S): Bartlett, Julie B.; Freeman, Sue; Kenny, Peter; Morley, Andrew; Whittamore, Paul
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
 SOURCE: PCT Int. Appl., 141 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020530	A1	20020314	WO 2001-SE1880	20010831
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HH, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, U2, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2417594	AA	20020314	CA 2001-2417594	20010831
AU 2001082833	A5	20020322	AU 2001-82833	20010831
EP 1317459	A1	20030611	EP 2001-961577	20010831
EP 1317459	B1	20040407		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013606	A	20030624	BR 2001-13606	20010831
JP 2004508376	T2	20040318	JP 2002-52151	20010831
AT 261772	E	20040415	AT 2001-961577	20010831
NZ 524011	A	20040827	NZ 2001-524011	20010831
PT 1317459	T	20040831	PT 2001-961577	20010831
ES 2217183	T3	20041101	ES 2001-1961577	20010831
ZA 2003000083	A	20041215	EE 2003-83	20010831
ZA 2003001013	A	20040505	ZA 2003-1013	20030205
US 2003232875	A1	20031218	US 2003-344506	20030210
NO 2003001024	A	20030305	NO 2003-1024	20030305
BG 107624	A	20040130	BG 2003-107624	20030310
HK 1055299	A1	20041021	HK 2003-107519	20031016
PRIORITY APPLN. INFO.:			GB 2000-21831	A 20000906
			WO 2001-SE1880	W 20010831

OTHER SOURCE(S): MARPAT 136:247405
 GI



I



II

AB Title compds. I [R1 = H, halo, NO2, CN, OH, (un)substituted alkyl, alkenyl, etc.; R2 = H, halo, NO2, CH2F, CHF2, CF3, amino, alkyl, alkenyl, alkoxy, etc.; R3 = H, alkyl; -X-Y-Z- is selected from -S-CR4=CR5-, -CR4=CR5-S-, -O-CR4=CR5-, -CR4=CR5-O-, -N=CR4-S-, -S-CR4=N-, -NR3-CR4=CR5- and -CR4=CR5-NR3- wherein R4 and R5 = independently H, halo, CN, alkyl, ureido, NO2, etc.; n = 0-4] or a pharmaceutically acceptable salt or an

in vivo hydrolyzable ester thereof were prepared possessing glycogen phosphorylase inhibitory activity (no data). Thus, II was prepared by amidation of 5-carboxy-2,3-dichloro-4H-thieno[3,2-b]pyrrole with 2-phenoxyethylamine. As glycogen phosphorylase inhibitors, I have value in the treatment of disease states associated with increased glycogen phosphorylase activity, e.g., type 2 diabetes. Pharmaceutical compns. containing I are described.



IT 403860-50-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (intermediate; preparation of thienopyrrolyl amides as glycogen phosphorylase inhibitors)

RN 403860-50-4 CAPLUS

CN Carbanic acid, [(1R,2R)-2-((2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl)amino]-2,3-dihydro-1H-inden-1-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 403859-86-9 CAPLUS


CN 4H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-((1R,2R)-2,3-dihydro-1-hydroxy-1H-inden-2-yl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 403859-88-1 CAPLUS


CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-(6-fluoro-2,3-dihydro-1-hydroxy-1H-inden-2-yl)- (9CI) (CA INDEX NAME)



RN 403859-98-3 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-((1R,2R)-2,3-dihydro-1-methoxy-1H-inden-2-yl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 403859-99-4 CAPLUS

CN Carbanic acid, [(1R,2R)-2-((2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl)amino]-2,3-dihydro-1H-inden-1-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

IT 403859-84-7P 403859-85-8P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of thienopyrrolyl amides as glycogen phosphorylase inhibitors)

RN 403859-84-7 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-((1S,2S)-2,3-dihydro-1-hydroxy-1H-inden-2-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 403859-85-8 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-((1R,2R)-2,3-dihydro-1-hydroxy-1H-inden-2-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 403859-83-6P 403859-86-9P 403859-88-1P

403859-98-3P 403859-99-4P 403860-01-5P

403860-02-6P 403860-03-7P 403860-05-5P

403860-06-0P 403860-69-5P 403860-70-8P

403860-72-0P 403860-73-1P 403860-74-2P

403860-75-3P 403860-76-4P 403860-78-6P

403860-79-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(target compound; preparation of thienopyrrolyl amides as glycogen phosphorylase inhibitors)

RN 403859-83-6 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-((1R,2R)-2,3-dihydro-1-hydroxy-1H-inden-2-yl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Absolute stereochemistry.



RN 403860-01-5 CAPLUS


CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-((1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl)-2,3-dichloro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 403860-00-4

CMF C16 H13 Cl2 N3 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 403860-02-6 CAPLUS


CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-((1R,2R)-1-(acetylamino)-2,3-dihydro-1H-inden-2-yl)-2,3-dichloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403860-03-7 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-(methylsulfonyl)amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 403860-05-9 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-(methylamino)-1H-inden-2-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 403860-04-8
CMF C17 H15 Cl2 N3 O S

Absolute stereochemistry.




CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 403860-73-1 CAPLUS
CN Carbamic acid, 12-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 403860-74-2 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-(1-amino-2,3-dihydro-1H-inden-2-yl)-2,3-dichloro- (9CI) (CA INDEX NAME)



RN 403860-75-3 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1-acetylamino)-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro- (9CI) (CA INDEX NAME)




RN 403860-76-4 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(2,3-dihydro-1-(methylsulfonyl)amino)-1H-inden-2-yl]- (9CI) (CA INDEX NAME)




RN 403860-06-0 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-(acetylaminomethyl)amino]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 403860-69-5 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-(2,3-dihydro-1-hydroxy-1H-inden-2-yl)- (9CI) (CA INDEX NAME)



RN 403860-70-8 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2-chloro-N-(2,3-dihydro-1-hydroxy-1H-inden-2-yl)- (9CI) (CA INDEX NAME)




RN 403860-72-0 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-(2,3-dihydro-1-methoxy-1H-inden-2-yl)- (9CI) (CA INDEX NAME)



RN 403860-78-6 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1-methylamino)-2,3-dihydro-1H-inden-2-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 403860-77-5
CMF C17 H15 Cl2 N3 O S




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 403860-79-7 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1-acetylaminomethyl)amino]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE